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R3The first cultivation of human 
embryonic stem cells in 998 quickly 
led to high hopes for regenerative 
medicine, damped only by ethical 
concerns prevailing, for instance, in 
Germany and parts of the USA. Now, 
however, two companies are in a 
race to start the first clinical trials of 
treatments using human embryonic 
stem (hES) cells, and efforts to create 
safer and more efficient ways towards 
induced pluripotent stem (iPS) cells 
are also beginning to bear fruit. 
Initially, it looked as though the 
company Geron, based at Thousand 
Oaks, California, would be the first 
to get clinical trials of hES cells 
going. The company applied for FDA 
approval for a trial using hES cells to 
treat spinal cord injury. However, the 
trial had to be postponed after cysts 
were observed in some of the animals 
on which the method had been tried. 
Now... two companies are in 
a race to start the first clinical 
trials of treatments using 
 human embryonic stem cells, 
and efforts to create safer and 
more efficient ways towards 
induced pluripotent stem cells 
are also beginning to bear fruit
In November, Advanced 
Cell Technology in Worcester, 
Massachusetts, filed an 
Investigational New Drug (IND) 
application with the FDA, essentially 
asking permission for a clinical trial 
of a treatment using hES cells to cure 
Stargardt’s macular dystrophy, which 
leads to blindness and has remained 
incurable so far. The new therapy 
involves growing retinal pigment 
epithelium cells from hES cells in the 
laboratory, and implanting these into 
the patient’s eye in the hope that they 
regenerate the damaged retina.
Robert Lanza, ACT’s Chief Scientific 
Officer, said: “After years of research 
and political debate, we’re finally on 
Progress with both embryonal and 
induced pluripotent stem cells is 
bringing clinical applications a step 
closer. Michael Gross reports.
Stem cell moves the verge of showing the potential clinical value of embryonic stem cell 
research. Our research clearly shows 
that stem-cell-derived retinal cells 
can rescue visual function in animals 
that otherwise would have gone blind. 
We are hopeful that the cells will be 
similarly efficacious in patients.”
 The company hopes to start its 
clinical trial this spring. At a later 
point, the company also hopes to 
extend the treatment of age-related 
macular degeneration, the most 
common cause of blindness in 
industrialised countries. 
Four other research groups aiming 
to develop hES-cell therapies have 
recently received a funding boost 
from the California Institute for 
Regenerative Medicine (CIRM) as 
part of a $250 million award scheme 
handed to 4 international research 
teams in the US, Canada, and the UK. 
CIRM was set up in 2004 as part of 
Proposition 7, which provided a total 
of $3 billion in research funding.
Meanwhile, researchers investigating 
the alternative approach using iPS 
cells have made rapid progress since 
the discovery that overexpression of a 
small number of genes in differentiated 
cells can turn back the clock of 
development both in mice and men. 
The original ‘four factor’ recipe 
involved the use of a retrovirus 
dumping the genetic cargo at random 
places in the genome. To make 
matters worse, one of the genes introduced was a known oncogene. 
Thus the cancer risk associated with 
these cell preparations ruled out any 
clinical ambitions. 
However, in the spring of 2009, 
Sheng Ding and his group at the 
Scripps Research Institute at La 
Jolla, California, could show that 
introduction of the corresponding 
proteins can also produce iPS cells, 
provided an additional chemical, 
valproic acid, is added to the mix. 
Later last year, the groups of Lee 
Rubin and Kevin Eggan at Harvard 
could show that small molecules can 
replace at least one of the factors, 
while Sheng Ding’s group could 
improve the efficiency of the ‘four 
factor’ recipe 200-fold with the help of 
kinase inhibitors. 
Thus, researchers can now produce 
iPS cells either efficiently or relatively 
safely without introducing specific 
cancer risks. However, Paul Fairchild, 
co-director of the Oxford Stem Cell 
Institute within the James Martin 2st 
Century School warns that with all 
stem cell preparations available so 
far there remains the possibility of an 
inherent cancer risks. 
Regarding the new substances 
used to turn back the development 
clock, Fairchild is concerned that 
by modifying critical intracellular 
signalling pathways involved in 
differentiation, the compounds 
themselves may enhance the 
likelihood of transformation.  An Moving: Potential clinical applications for human stem cells are advancing. (Photo: Professor 
Miodrag Stojkovic/Science Photolibrary.) 
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R4additional risk, he says, comes from 
the very property that regenerative 
medicine wants replacement organs 
to possess, namely invisibility to the 
immune system. “Tissues derived 
from iPSC may share with ES cells 
the potential to display immune 
privilege which may provide a ‘safe 
haven’ in which rare transformed 
cells may develop into tumours or 
viral pathogens may flourish under the 
radar of the host immune system. This 
will doubtlessly need to be addressed 
before iPSC could ever be used 
therapeutically,” Fairchild says. 
So replacement organs made 
from hES or iPS cells are not going 
to become available this year, but 
with clinical trials on the horizon, we 
can expect further exciting progress, 
slowly bringing this field closer to real-
world clinical applications. 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.ukWhile the events in Copenhagen 
were dominated by the world’s 
largest countries, the issue of climate 
change is of great concern to many 
smaller island and coastal states and 
their inhabitants. One internationally 
renowned artist has launched an 
exhibition in his native island of  
St Lucia to highlight his perceived 
threat of climate change. “I don’t know 
if there is very much world leaders can 
do about what is going to happen –  
because it is going to happen,” 
says Llewellyn Xavier. “Indeed it is 
already happening. What I think we 
as mankind can do is recognize that 
there is global degradation; that there 
is climate change – whether it’s a 
cycle or caused by man,” he says.
“My concern is what we are doing 
about it,” he told St Lucia’s Mirror 
newspaper. “Are we going as usual 
flying these aircraft…? Are we going 
to ban these fossil fuels? Are we going 
to air-condition houses and put even 
more gases into the atmosphere?”
Xavier’s latest exhibition coincided 
with the opening of the climate 
change conference in Copenhagen.
Xavier has permanent collections in 
the Metropolitan Museum of Art and 
the Museum of Modern Art in New 
York and the Smithsonian and State 
Department in Washington DC. He also 
has paintings in the Victoria and Albert 
Museum in London; at Oxford University 
and the Art Gallery of Ontario.
He will be exhibiting work in 
the series ‘Global Council for 
the Restoration of the Earth’s 
Environment’ at airports, universities, 
hospitals and public places which he 
hopes can begin in February.
Many smaller and coastal states are 
keen to promote the environmental 
threat of climate change. Nigel 
Williams reports.
Island worries
There are four phases of work on 
display at the Caribbean Art Gallery, 
focusing on the environment. Xavier 
wants the series to show continuity in 
his work in environmental awareness 
over the last 20 years.
And he is concerned about the 
content of the whole exhibition. “You 
have to be very careful that you are 
not producing propaganda art; that 
you are not producing art simply 
for the sake of making a political 
point, or scoring points for that 
matter.”
Concern: St Lucian artist Llewellyn Xavier has a new exhibition highlighting environmental 
 issues. (Scarlet Macaw by Llewellyn Xavier: llewellynxavier.com)
